ZUSDURI launch propels UroGen Q2 revenue to $72.5M, sharply narrows loss, and lifts guidance
URGN has more than doubled off its 52-week low of $15.86.
Summary
UroGen Pharma posted Q2 2026 revenue of $72.5 million, fueled by $50.4 million in ZUSDURI sales, and narrowed its net loss to $14.4 million. Full-year operating expense guidance was raised to $260–$270 million to support the launch and pipeline.
Key Events · Earnings and Guidance · URGN
-
ZUSDURI Launch Drives Revenue Surge
ZUSDURI generated $50.4 million in Q2 2026, up 73% from Q1, with 1,444 activated sites and 452 prescribers. Total revenue reached $72.5 million, nearly triple the $24.2 million in Q2 2025.
-
Net Loss Narrows Significantly
Net loss improved to $14.4 million ($0.28/share) from $49.9 million ($1.05/share) a year ago, reflecting operating leverage as revenue scales.
-
Full-Year Operating Expense Guidance Raised
UroGen increased 2026 operating expense guidance to $260–$270 million (from prior undisclosed level) to accelerate ZUSDURI commercial investment and pipeline development, including UGN-103 and UGN-501 trials.
-
Cash Position and Balance Sheet
Cash and marketable securities totaled $108.0 million as of June 30, 2026. Total shareholders' deficit was $132.4 million, reflecting accumulated losses and financing obligations.
Analysis · URGN · Life Sciences
A dramatic commercial inflection took hold in the second quarter as the ZUSDURI launch vaulted total revenue to $72.5 million, nearly tripling the prior-year period. The net loss contracted to $14.4 million from $49.9 million a year ago, and management raised full-year operating expense guidance to accelerate investment behind the launch. With $108 million in cash and an NDA submission for UGN-103 on track this quarter, the results underscore both commercial momentum and pipeline progress, though the increased spending and negative shareholders' equity warrant attention.
At the time of this filing, URGN was trading at $41.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $15.86 to $43.93. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.